Crescent Biopharma, Inc. (CBIO)

Name: Crescent Biopharma, Inc. (CBIO) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name CRESCENT BIOPHARMA, INC. · CIK 0001253689 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Crescent Biopharma, Inc. reported revenue of $10.84M. Over the twelve months to 2026-06-30, revenue was $11.88M.

Key ratios (year ended 2025-12-31)

n/m

Operating margin

n/m

Net margin

-75.8%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-15

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$11.88M	$10.84M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	$152.67M	$138.09M	$14.26M	$20.07M	$28.39M	$47.49M	$44.93M	$47.03M	$40.09M	$24.10M	$23.28M
Operating Income	-$168.47M	-$152.63M	-$40.04M	-$39.28M	-$47.40M	-$63.45M	-$51.51M	-$61.39M	-$51.50M	-$33.93M	-$31.91M
Net Income	-$165.12M	-$153.94M	-$37.88M	-$36.90M	-$46.69M	-$63.43M	-$51.03M	-$57.89M	-$48.27M	-$33.28M	-$31.81M
EPS (Diluted)	n/a	n/a	-$0.59	-$0.58	-$0.89	-$1.23	-$1.12	-$1.34	n/a	n/a	n/a
Total Assets	$182.76M	$240.29M	$35.62M	$45.32M	$51.81M	$94.35M	$142.83M	$167.97M	$214.84M	$128.58M	$42.39M
Total Liabilities	$19.50M	$37.28M	$47.10M	$6.90M	$8.88M	$12.74M	$14.61M	$13.77M	$9.37M	$8.88M	$7.09M
Shareholders' Equity	$163.25M	$203.01M	-$15.48M	$38.41M	$42.93M	$81.60M	$128.22M	$154.20M	$205.46M	$119.70M	$35.30M
Cash & Equivalents	$171.59M	$213.19M	$34.77M	$41.79M	$47.87M	$90.25M	$137.04M	$158.20M	$209.92M	$123.92M	$40.04M
Operating Cash Flow	-$72.68M	-$71.53M	-$31.10M	-$34.88M	-$46.46M	-$57.49M	-$39.24M	-$51.98M	-$43.33M	-$29.77M	-$29.73M
Capital Expenditures	$939.0K	$919.0K	$10.0K	$21.4K	$84.2K	$14.9K	$68.5K	$144.9K	$125.6K	$294.1K	$704.2K
Free Cash Flow	-$73.62M	-$72.45M	-$31.11M	-$34.90M	-$46.54M	-$57.50M	-$39.31M	-$52.13M	-$43.46M	-$30.06M	-$30.44M
Shares Outstanding	27.76M	27.56M	1.02M	64.39M	54.38M	52.31M	49.02M	43.47M	43.16M	34.36M	23.25M
Weighted Average Diluted Shares	n/a	n/a	64.48M	63.34M	52.53M	51.45M	45.72M	43.25M	n/a	n/a	n/a
EPS (Basic)	n/a	n/a	-$0.59	-$0.58	-$0.89	-$1.23	-$1.12	-$1.34	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView